EURURO Vol. 72 No. 6

884 1030

Author contributions: Liam Bourke had full access to all the data in the
study and takes responsibility for the integrity of the data and the
accuracy of the data analysis.
Study concept and design: Bourke.
Acquisition of data: Bourke, Lardas, Liew.
Analysis and interpretation of data: Bourke, Lardas, Liew.
Drafting of the manuscript: Lardas.
Critical revision of the manuscript for important intellectual content: van
den Bergh, De Santis, Bellmunt, Van den Broeck, Cornford, Cumberbatch,
Fossati, Gross, Henry, Bolla, Briers, Joniau, Lam, Mason, Mottet, van der
Poel, Rouvie`re, Schoots, Wiegel, Willemse, Yuan.
Statistical analysis: None.
Obtaining funding: None.
Administrative, technical, or material support: None.
Supervision: Bourke.
Other: None.
Financial disclosures: Liam Bourke certifies that all conflicts of interest,
including specific financial interests and relationships and affiliations
relevant to the subject matter or materials discussed in the manuscript
(eg, employment/affiliation, grants or funding, consultancies, honorar-
ia, stock ownership or options, expert testimony, royalties, or patents
filed, received, or pending), are the following: Maria De Santis is a
company consultant for GlaxoSmithKline, Janssen, Bayer, Novartis,
Pierre Fabre, Astellas, Amgen, Eisai, ESSA, Merck, and Synthon; has
received company speaker honoraria from Pfizer, Takeda, Sanofi
Aventis, Shionogi, Celgene, and Teva OncoGenex; has participated in
trials for Pierre Fabre, Astellas, Exelixis, Bayer, and Roche; has received
fellowship and travel grants from Bayer, Novartis, Ferring, Astellas,
Sanofi Aventis, and Janssen; has received grant and research support
from Pierre Fabre; has received honoraria from AstraZeneca; and is
associated with Amgen. Joaquim Bellmunt is a company consultant for
Janssen, Astellas, Pierre Fabre, Genentech, Merck, Ipsen, Pfizer,
Novartis, and Sanofi Aventis, and has received research support from
Takeda, Novartis, and Sanofi, and travel grants from Pfizer and Pierre
Fabre. Philip Cornford is a company consultant for Astellas, Ipsen, and
Ferring; receives company speaker honoraria from Astellas, Janssen,
Ipsen, and Pfizer; participates in trials from Ferring; and receives
fellowships and travel grants from Astellas and Janssen. Malcolm D.
Mason is a company consultant for Bristol-Myers Squibb, Janssen,
Bayer, Sanofi, and Dendreon, and receives company speaker honoraria
from Takeda and Bayer. Michel Bolla has received company speaker
honoraria from Ipsen and Astellas, honoraria or consultation fees from
Janssen, and fellowship and travel grants from Janssen, AstraZeneca,
and Astellas. Erik Briers has received grant and research support from
the European Association of Urology; is an ex officio board member for
Europa UOMO; is an ethics committee and advisory group member for
REQUITE; is a patient advisory board member for PAGMI; and is a
member of SCA and EMA PCWP. Steven Joniau is a company consultant
for Astellas, Ipsen, Bayer, Sanofi, and Janssen; has received company
speaker honoraria from Astellas, Amgen, Bayer, Sanofi, Janssen, and
Ipsen; has participated in trials for Astellas, Janssen, and Bayer; has
received fellowship and travel grants from Astellas, Amgen, Bayer,
Sanofi, Janssen, Ipsen, and Pfizer; and has received grant and research
support from Astellas, Bayer, and Janssen. Thomas B. Lam is a company
consultant for and has received company speaker honoraria fromPfizer,
GSK, Astellas, and Ipsen. MalcolmD. Mason is a company consultant for
Bristol-Myers Squibb, Janssen, Bayer, Sanofi, and Dendreon, and receives
company speaker honoraria from Takeda and Bayer. Nicolas Mottet has
received grant and research support from Takeda Pharmaceutical,
Millenium, Astellas, Pierre Fabre, Sanofi, and Pasteur, and has received
honoraria or consultation fees from Takeda Pharmaceutical, Millennium,
Jansen, Astellas, BMS, Bayer, Ipsen, Ferring, Novartis, Nucle´tron, Pierre
Fabre, Sanofi, and Zeneca. Henk G. van der Poel is a company consultant
for Intuitive Surgical, has participated in trials for Astellas and Steba
Biotech, and has received grant and research support from Astellas.
Olivier Rouvie`re is a company consultant for EDAP-TMS, Bracco, and
Philips; has received company speaker honoraria from EDAP-TMS, Bracco,
and Philips; and has participated in trials for EDAP-TMS and Bracco.
Thomas Wiegel has received company speaker honoraria from Astellas,
Takeda, Hexal, Ipsen, Janssen-Cilac, and Ferring. Michael Lardas, Matthew
Liew, Roderick C.N. van den Bergh, Thomas Van den Broeck, Marcus G.
Cumberbatch, Nicola Fossati, Tobias Gross, Ann M. Henry, Ivo G. Schoots,
Peter-Paul M. Willemse, Cathy Yuhong Yuan, and Liam Bourke have
nothing to disclose.
Funding/Support and role of the sponsor: None.
Appendix B. Supplementary data
Supplementary data associated with this article can be
found, in the online version, at
References
[1]
[2] Mottet N, Bellmunt J, Briers E, et al. Guidelines on Prostate Cancer,
2016.
.
[3]
[4]
[5]
[6]
[7] Morris C, Gibbons E, Fitzpatrick R. A structured review of patient-
reported outcome measures for men with prostate cancer. Univer-
sity of Oxford; 2009.
[8]
[9] Reeves BR, Deeks JJ, Higgins JPT, Wells GA, on behalf of the Cochrane
Non-Randomised Studies Methods Group. Chapter 13 Including
non-randomised studies. In: Higgins JPT, Green S, editors. Cochrane
handbook for systematic reviews of interventions v.5.0.2. The
Cochrane Collaboration; 2011.
[10]
.
[11]
.
[12]
.
E U R O P E A N U R O L O G Y 7 2 ( 2 0 1 7 ) 8 6 9 – 8 8 5 884